"A PHASE 1/PHASE 2 CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF A COMBINATION OF MK-4280 AND PEMBROLIZUMAB (MK-3475) IN PARTICIPANTS WITH HEMATOLOGIC MALIGNANCIES."

Registry ID

MK-4280-003

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

MERCK CANADA INC

Start date

2024-05-01

Last update

2018-09-18

Conditions

• HEMATOLOGICAL MALIGNANCIES

Related clinical trials

• LIGHTBEAM-U01 SUBSTUDY 01A: A PHASE 1/2 SUBSTUDY TO EVALUATE THE SAFETY AND EFFICACY OF ZILOVERTAMAB VEDOTIN IN PEDIATRIC AND YOUNG ADULT PARTICIPANTS WITH HEMATOLOGIC MALIGNANCIES OR SOLID TUMORS
• AN OPEN-LABEL, MULTICENTER, ROLL-OVER STUDY FOR PATIENTS WHO HAVE COMPLETED A PRIOR NOVARTIS-SPONSORED SABATOLIMAB (MBG453) STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED TREATMENT WITH SABATOLIMAB
• PHASE 1/2 STUDY OF 9-ING-41, A GLYCOGEN SYNTHASE KINASE-3 BETA (GSK-3B) INHIBITOR, AS A SINGLE AGENT AND COMBINED WITH CHEMOTHERAPY, IN PATIENTS WITH REFRACTORY HEMATOLOGIC MALIGNANCIES OR SOLID TUMORS
• A PHASE 2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MK- 7684A (MK-7684 [VIBOSTOLIMAB] WITH MK-3475 [PEMBROLIZUMAB] COFORMULATION) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY HEMATOLOGICAL MALIGNANCIES
• A PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MK-1026 IN PARTICIPANTS WITH HEMATOLOGIC MALIGNANCIES
• CANADIAN-LED IMMUNOTHERAPIES IN CANCER: CLIC-1901 FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY CD19 POSITIVE HEMATOLOGIC MALIGNANCIES

View on source registry